Parvovirus 4 infection and clinical outcome in high-risk populations

Ruth Simmons; Colin Sharp; C. Patrick McClure; Janine Rohrbach; Helen Kovari; Eleni Frangou; Peter Simmonds; Will Irving; Andri Rauch; Paul Bowness; Paul Klenerman

doi:10.1093/infdis/jis291

Parvovirus 4 infection and clinical outcome in high-risk populations

Ruth Simmons^*
, Colin Sharp
, C. Patrick McClure
, Janine Rohrbach
, Helen Kovari
, Eleni Frangou
, Peter Simmonds
, Will Irving
, Andri Rauch
, Paul Bowness
, Paul Klenerman

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

Abstract

Parvovirus 4 (PARV4) is a DNA virus frequently associated with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections, but its clinical significance is unknown. We studied the prevalence of PARV4 antibodies in 2 cohorts of HIV-and HCV-infected individuals (n = 469) and the correlations with disease status. We found that PARV4 infection frequently occurred in individuals exposed to bloodborne viruses (95 in HCV-HIV coinfected intravenous drug users [IDUs]). There were no correlations between PARV4 serostatus and HCV outcomes. There was, however, a significant association with early HIV-related symptoms, although because this was tightly linked to both HCV status and clinical group (IDU), the specific role of PARV4 is not yet clear.

Original language	English
Pages (from-to)	1816-1820
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	205
Issue number	12
DOIs	https://doi.org/10.1093/infdis/jis291
Publication status	Published - 15 Jun 2012
Externally published	Yes

Bibliographical note

Funding Information:
Financial support. This work was supported by the Wellcome Trust (including WT091663MA), the National Institute of Health (NIH) (National Institute of Allergy and Infectious Diseases U19 AI082630/01], SHCS (grant 633), Swiss National Science Foundation (grants 34277 3345-062041 and 324730-116862), the Medical Research Council UK, and the Biomedical Research Centre. The development and use of the serological assay for anti-PARV4 antibodies was supported by an unrestricted investigator-initiated grant from Baxter Healthcare and by the NIH, National Institute of Child Health and Human Development (R01 HD41224). Funding to pay the Open Access publication charges for this article was provided by the Wellcome Trust. Potential conflicts of interest. All authors: No reported conflicts.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/infdis/jis291

Cite this

@article{bbbf8df6c57249a08febb280904a0969,

title = "Parvovirus 4 infection and clinical outcome in high-risk populations",

abstract = "Parvovirus 4 (PARV4) is a DNA virus frequently associated with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections, but its clinical significance is unknown. We studied the prevalence of PARV4 antibodies in 2 cohorts of HIV-and HCV-infected individuals (n = 469) and the correlations with disease status. We found that PARV4 infection frequently occurred in individuals exposed to bloodborne viruses (95 in HCV-HIV coinfected intravenous drug users [IDUs]). There were no correlations between PARV4 serostatus and HCV outcomes. There was, however, a significant association with early HIV-related symptoms, although because this was tightly linked to both HCV status and clinical group (IDU), the specific role of PARV4 is not yet clear.",

author = "Ruth Simmons and Colin Sharp and McClure, \{C. Patrick\} and Janine Rohrbach and Helen Kovari and Eleni Frangou and Peter Simmonds and Will Irving and Andri Rauch and Paul Bowness and Paul Klenerman",

note = "Funding Information: Financial support. This work was supported by the Wellcome Trust (including WT091663MA), the National Institute of Health (NIH) (National Institute of Allergy and Infectious Diseases U19 AI082630/01], SHCS (grant 633), Swiss National Science Foundation (grants 34277 3345-062041 and 324730-116862), the Medical Research Council UK, and the Biomedical Research Centre. The development and use of the serological assay for anti-PARV4 antibodies was supported by an unrestricted investigator-initiated grant from Baxter Healthcare and by the NIH, National Institute of Child Health and Human Development (R01 HD41224). Funding to pay the Open Access publication charges for this article was provided by the Wellcome Trust. Potential conflicts of interest. All authors: No reported conflicts.",

year = "2012",

month = jun,

day = "15",

doi = "10.1093/infdis/jis291",

language = "English",

volume = "205",

pages = "1816--1820",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Parvovirus 4 infection and clinical outcome in high-risk populations

AU - Simmons, Ruth

AU - Sharp, Colin

AU - McClure, C. Patrick

AU - Rohrbach, Janine

AU - Kovari, Helen

AU - Frangou, Eleni

AU - Simmonds, Peter

AU - Irving, Will

AU - Rauch, Andri

AU - Bowness, Paul

AU - Klenerman, Paul

N1 - Funding Information: Financial support. This work was supported by the Wellcome Trust (including WT091663MA), the National Institute of Health (NIH) (National Institute of Allergy and Infectious Diseases U19 AI082630/01], SHCS (grant 633), Swiss National Science Foundation (grants 34277 3345-062041 and 324730-116862), the Medical Research Council UK, and the Biomedical Research Centre. The development and use of the serological assay for anti-PARV4 antibodies was supported by an unrestricted investigator-initiated grant from Baxter Healthcare and by the NIH, National Institute of Child Health and Human Development (R01 HD41224). Funding to pay the Open Access publication charges for this article was provided by the Wellcome Trust. Potential conflicts of interest. All authors: No reported conflicts.

PY - 2012/6/15

Y1 - 2012/6/15

N2 - Parvovirus 4 (PARV4) is a DNA virus frequently associated with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections, but its clinical significance is unknown. We studied the prevalence of PARV4 antibodies in 2 cohorts of HIV-and HCV-infected individuals (n = 469) and the correlations with disease status. We found that PARV4 infection frequently occurred in individuals exposed to bloodborne viruses (95 in HCV-HIV coinfected intravenous drug users [IDUs]). There were no correlations between PARV4 serostatus and HCV outcomes. There was, however, a significant association with early HIV-related symptoms, although because this was tightly linked to both HCV status and clinical group (IDU), the specific role of PARV4 is not yet clear.

AB - Parvovirus 4 (PARV4) is a DNA virus frequently associated with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections, but its clinical significance is unknown. We studied the prevalence of PARV4 antibodies in 2 cohorts of HIV-and HCV-infected individuals (n = 469) and the correlations with disease status. We found that PARV4 infection frequently occurred in individuals exposed to bloodborne viruses (95 in HCV-HIV coinfected intravenous drug users [IDUs]). There were no correlations between PARV4 serostatus and HCV outcomes. There was, however, a significant association with early HIV-related symptoms, although because this was tightly linked to both HCV status and clinical group (IDU), the specific role of PARV4 is not yet clear.

UR - https://www.scopus.com/pages/publications/84861534682

U2 - 10.1093/infdis/jis291

DO - 10.1093/infdis/jis291

M3 - Article

C2 - 22492853

AN - SCOPUS:84861534682

SN - 0022-1899

VL - 205

SP - 1816

EP - 1820

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 12

ER -

Parvovirus 4 infection and clinical outcome in high-risk populations

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this